- Home
- ROIV vs CRDO Comparison
ROIV vs CRDO Comparison
Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CRDO
- Stock Information
- Founded
- ROIV 2014
- CRDO 2008
- Country
- ROIV United Kingdom
- CRDO Cayman Islands
- Employees
- ROIV N/A
- CRDO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CRDO Semiconductors
- Sector
- ROIV Health Care
- CRDO Technology
- Exchange
- ROIV Nasdaq
- CRDO Nasdaq
- Market Cap
- ROIV 8.4B
- CRDO 7.3B
- IPO Year
- ROIV N/A
- CRDO 2022
- Fundamental
- Price
- ROIV $10.87
- CRDO $61.78
- Analyst Decision
- ROIV Buy
- CRDO Strong Buy
- Analyst Count
- ROIV 4
- CRDO 10
- Target Price
- ROIV $17.50
- CRDO $68.00
- AVG Volume (30 Days)
- ROIV 5.2M
- CRDO 3.5M
- Earning Date
- ROIV 05-29-2025
- CRDO 06-02-2025
- Dividend Yield
- ROIV N/A
- CRDO N/A
- EPS Growth
- ROIV N/A
- CRDO N/A
- EPS
- ROIV N/A
- CRDO 0.03
- Revenue
- ROIV $122,585,000.00
- CRDO $327,532,000.00
- Revenue This Year
- ROIV N/A
- CRDO $125.51
- Revenue Next Year
- ROIV N/A
- CRDO $58.82
- P/E Ratio
- ROIV N/A
- CRDO $2,003.44
- Revenue Growth
- ROIV 140.04
- CRDO 99.38
- 52 Week Low
- ROIV $8.73
- CRDO $18.98
- 52 Week High
- ROIV $13.06
- CRDO $86.69
- Technical
- Relative Strength Index (RSI)
- ROIV 51.00
- CRDO 72.12
- Support Level
- ROIV $10.58
- CRDO $57.21
- Resistance Level
- ROIV $11.07
- CRDO $63.66
- Average True Range (ATR)
- ROIV 0.30
- CRDO 3.00
- MACD
- ROIV -0.04
- CRDO 0.72
- Stochastic Oscillator
- ROIV 30.21
- CRDO 89.56
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.